查看文章

had a history of coronary artery disease. 13 Subcutaneous dosing regimens and safety of REGN727 were tested in addition to aggressive LDL-lowering therapy with high doses of strong statins (simvastatin, atorvastatin, or rosuvastatin) in all patients, and 55 (71%) also used ezetimibe. The mean reduction in LDL cholesterol after 12 weeks of treatment confirmed significant dosedependent effects ranging from 29% to 68%, compared with 11% in the placebo group. The optimum dose was 150 mg with an interval of 2 weeks. Concentrations of non-HDL cholesterol and apolipoprotein B were significantly reduced, and those of HDL cholesterol and apolipoprotein A1 increased. The mean concentration of lipoprotein (a) decreased as well, although not significantly. Mild reactions at injection sites were common, but no serious adverse events were reported, although higher doses than previously were tested. The …